Лекарственное поражение почек у больных ВИЧ-инфекцией: клинические варианты, возможности предупреждения


Н.А. Мухин, В.В. Фомин

ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, Москва
Обсуждаются поражение почек, в т. ч. связанное с высокоактивной антиретровирусной терапией, у больных ВИЧ-инфекцией; его клинические варианты (острая почечная недостаточность, канальцевые дисфункции), подходы к диагностике и профилактике.

Литература


1. Winston J.A. HIV and CKD epidemiology. Adv. Chronic Kidney Dis. 2010;17(1):19–25.
2. Gupta S.K., Eustace J.A., Winston J.A. et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 2005;40:1559–1585.
3. Berns J.S., Kasbekar N. Highly active antiretroviral therapy and the kidney: and update on antiretroviral medications for nephrologists. Clin. J. Am. Soc. Nephrol. 2006;1:117–129.
4. Perazella M.A. Acute renal failure in HIV-infected patients: a brief review of common causes. Am. J. Med. Sci. 2000;319(6):385–391.
5. Izzedine H., Baumelou A., Deray G. Acute renal failure in HIV patients. Nephrol. Dial. Transplant. 2007;22:2757–2762.
6. Franceschini N., Napravnik S., Eron J.J. et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 2005;67:1526–1531.
7. Wyatt C.M., Arons R.R., Klotman P.E. et al. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006;204561–204565.
8. Peraldi M.N., Maslo C., Akposso K. et al. Acute renal failure in the course of retrospective study of ninety-two patients and sixty renal biopsies. Nephrol. Dial. Transplant. 1999;14(6):1578–1585.
9. Nicolau Laparra M.C., Martínez F., Giner V. et al. Temporal evolution of renal involvement in a necropsy study of HIV patients from the pre and HAART eras. Nefrologia. 2010;30(4):420–426.
10. Joshi M.K., Liu H.H. Acute rhabdomyolysis and renal failure in HIV-infected patients: risk factors, presentation, and pathophysiology. AIDS Patient Care STDS. 2000;14(10):541–548.
11. Roe J., Campbell L.J., Ibrahim F. et al. HIV care and the incidence of acute renal failure. Clin. Infect. Dis. 2008;47(2):242–249.
12. Overton E.T., Nurutdinova D., Freeman J. et al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med. 2009;10(6):343–350.
13. Ibrahim F., Naftalin C., Cheserem E. et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS. 2010;24(14):2239–2244.
14. Crum-Cianflone N., Ganesan A., Teneza-Mora N. et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010;24(6):353–360.
15. Izzedine H., Hulot J.S., Vittecoq D. et al. Study 903 Team. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant. 2005;20:743–746.
16. Barrios A., García-Benayas T., González-Lahoz J. et al. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004;18(6):960–963.
17. Gallant J.E., Winston J.A., De Jesus E. et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22(16):2155–2163.
18. Mauss S., Berger F., Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005;19:93–95.
19. Madeddu G., Bonfanti P., De Socio G.V. et al.; CISAI Group. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed. Pharmacother. 2008;62(1):6–11.
20. Jones R., Wolf E., Hoffmann C., Procaccianti M. et al. Long-term consequences of treatment interruptions in chronically HIV-1 infected patients. Eur. J. Med. Res. 2005;10(2):56–62.
21. Jones R., Stebbing J., Nelson M. et al. Renal dysfunction with tenofovir DF containing HAART regimens is not observed more frequently: a cohort and case-control study. J. AIDS 2001;37:1489–1495.
22. Psevdos G. Jr., Gonzalez E., Sharp V. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. AIDS Read. 2009;19(6):245–248.
23. Riordan A., Judd A., Boyd K. et al.; Collaborative HIV Paediatric Study. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr. Infect. Dis. J.
2009;28(3):204–209.
24. Bpharm S.M., Talbot A., Trottier B. et al. Acute renal failure in four HIVinfected patients: Potential association with tenofovir and nonsteroidal antiinflammatory drugs. Can. J. Infect. Dis. Med. Microbiol. 2008;19(1):75–76.
25. Izzedine H., Launay-Vacher V., Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS 2005;19:455–462.
26. Quimby D., Brito M.O. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read. 2005;15(7):357–364.
27. Badiou S., De Boever C.M., Terrier N. et al. Is tenofovir involved in hypophosphatemia and decrease in tubular prosphate reabsorbtion in HIVpositive adults? J. Infect. 2006;52:335–338.
28. Harmouche H., Le Bras P., Bignani O. et al. Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir. Rev. Med. Interne. 2005;26(6):522–523.
29. Callens S., De Roo A., Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J. Infect. 2003;47(3):262–263.
30. D©Ythurbide G., Goujard C., Mechai F. et al. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrol. Dial. Transplant. 2007; 22(12):3656–3659.
31. de la Prada F.J., Prados A.M., Tugores A. et al. Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir. Nefrologia. 006;26(5):626–630.
32. Hall A.M., Hendry B.M., Nitsch D. et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am. J. Kidney Dis. 2011;57(5):773–780.
33. Gatanaga H., Tachikawa N., Kikuchi Y. et al. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res. Hum. Retroviruses. 2006;22(8):744–748.
34. Izzedine H., Launay-Vacher V., Aymard G. et al. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron. 2001;89(1):62–67.
35. Post F.A., Moyle G.J., Stellbrink H.J. et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT Study. J. Acquir. Immune Defic. Syndr. 2010;55(1):49–57.


Об авторах / Для корреспонденции


Мухин Н.А. – академик РАМН, профессор, заведующий кафедрой терапии и профболезней медико-профилактического факультета, директор клиники нефрологии, внутренних и профессиональных болезней им. Е.М. Тареева Университетской клинической больницы № 3 ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.;
Фомин В.В. – профессор кафедры терапии и профболезней медико-профилактического факультета, декан факультета довузовского образования ГОУ ВПО “Первый МГМУ им. И.М. Сеченова”
Минздравсоцразвития России, д.м.н. E-mail: fomin_vic@mail.ru


Похожие статьи


Бионика Медиа